1932

Abstract

My mother, Leonore, was diagnosed with Huntington's disease (HD) in 1968 at age 53. I was 23, my sister Alice 26, and our father, Milton Wexler, 60 years old. The same year, our father created the Hereditary Disease Foundation (HDF), dedicated to finding treatments and cures for HD. HD is an autosomal dominant, neurodegenerative disorder. Alice and I each have a 50% chance of inheriting and dying from the disorder. Over the past 43 years, we have been proud to change the face of science. Through Milton Wexler Interdisciplinary Workshops, judicious funding, and focusing on innovation and creativity, the HDF is an integral partner in key discoveries. The HDF recruited and supported >100 scientists worldwide who worked together as the Huntington's Disease Collaborative Research Group in a successful ten-year search for the HD gene. We found a DNA marker for the HD gene in 1983—the first marker to be found when the chromosomal location was unknown. We isolated the HD gene itself a decade later. These breakthroughs helped launch the Human Genome Project. We supported creating the first mouse model of HD and many other model systems. Currently, we focus on gene silencing, among other approaches, to create new treatments and cures.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-050710-134457
2012-02-18
2024-04-18
Loading full text...

Full text loading...

/deliver/fulltext/med/63/1/annurev-med-050710-134457.html?itemId=/content/journals/10.1146/annurev-med-050710-134457&mimeType=html&fmt=ahah

Literature Cited

  1. Wexler M.1.  2002. Hereditary Disease Foundation. A Look Through the Rearview Mirror331–37 Bloomington, IN: Xlibris Corp.343 [Google Scholar]
  2. Wexler A.2.  1996. Mapping Fate: A Memoir of Family, Risk, and Genetic Research105, 173, 177 Berkeley and Los Angeles: Univ. Calif. Press321
  3. 3. Hereditary Disease Foundation http://www.hdfoundation.org
  4. Botstein D, White RL, Skolnick M. 4.  et al. 1980. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet. 32:3314–31 [Google Scholar]
  5. Brown MS, Dana SE, Goldstein JL. 5.  1974. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J. Biol. Chem. 249:3789–96 [Google Scholar]
  6. 1973. Centennial Symposium on Huntington's Chorea. Adv. Neurol. 14–5
  7. Negrette A.7.  1955. Corea de Huntington: Estudio de Una Sola Familia a Traves de Varias Genereaciones Maracaibo, Venezuela: Univ. Zulia, Maracaibo
  8. 8. Huntington Study Group 1996. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Disord. 11:2136–42 [Google Scholar]
  9. Young AB, Shoulson I, Penney JB. 9.  et al. 1986. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 36:244–49 [Google Scholar]
  10. Penney JB, Young AB, Shoulson I. 10.  et al. 1990. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord. 5:293–99 [Google Scholar]
  11. Gusella JF, Wexler NS, Conneally PM. 11.  et al. 1983. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306:5940234–38 [Google Scholar]
  12. Watson JD, Berry A. 12.  2003. DNA: The Secret of Life303 New York: Alfred A. Knopf
  13. 13. The Huntington's Disease Collaborative Research Group 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971–83 [Google Scholar]
  14. Angier N.14.  1993. Researchers locate gene that triggers Huntington's illness. New York Times Mar. 24 A1
  15. 15. The US-Venezuela Collaborative Research Project and Wexler NS 2004. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl. Acad. Sci. USA 101:153498–503 [Google Scholar]
  16. Wexler NS, Young AB, Tanzi RE. 16.  et al. 1987. Homozygotes for Huntington's disease. Nature 326:194–97 [Google Scholar]
  17. Duyao MP, Ambrose CM, Myers RH. 17.  et al. 1993. Trinucleotide repeat length: instability and age of onset in Huntington's disease. Nat. Genet. 4:387–92 [Google Scholar]
  18. Leeflang EP, Zhang L, Tavaré S. 18.  et al. 1995. Single sperm analysis of the trinucleotide repeats in the Huntington's disease gene: quantification of the mutation frequency spectrum. Hum. Mol. Genet. 4:91519–26 [Google Scholar]
  19. Andresen JM, Gayán J, Cherny SS. 19.  et al. 2006. Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J. Med. Genet. 44:44–50 [Google Scholar]
  20. Andresen JM, Gayán J, Djoussé L. 20.  et al. 2006. The relationship between CAG repeat length and age of onset differs for Huntington's disease patients with juvenile onset or adult onset. Ann. Hum. Gen. 71:295–301 [Google Scholar]
  21. Gayán J, Brocklebank D, Andresen JM. 21.  et al. 2008. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet. Epidemiol. 32:5445–53 [Google Scholar]
  22. Brocklebank D, Gayán J, Andresen JM. 22.  et al. 2009. Repeat instability in the 27–39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications. Am. J. Med. Genet. B Neuropsychiatr Genet. 150B:3425–29 [Google Scholar]
  23. Li J-L, Hayden MR, Almqvis EW. 23.  et al. 2003. A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS Study. Am. J. Hum. Genet. 73:682–87 [Google Scholar]
  24. Mangiarini L, Sathasivam K, Seller M. 24.  et al. 1996. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:3493–506 [Google Scholar]
  25. Davies SW, Turmaine M, Cozens BA. 25.  et al. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–48 [Google Scholar]
  26. Yamamoto A, Lucas JJ, Hen R. 26.  2000. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101:157–66 [Google Scholar]
  27. Southwell AL, Ko J, Patterson PH. 27.  2009. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J. Neurosci. 29:4313589–602 [Google Scholar]
  28. Snyder-Keller A, McLear JA, Hathorn T. 28.  et al. 2010. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J. Neuropathol. Exp. Neurol. 69:101078–85 [Google Scholar]
  29. Tam S, Spiess C, Auyeung W. 29.  et al. 2009. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat. Struct. Mol. Biol. 16:121279–85 [Google Scholar]
  30. Thompson LM, Aiken CT, Kaltenbach LS. 30.  et al. 2009. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J. Cell Biol. 187:71083–99 [Google Scholar]
  31. Gray M, Shirasaki DI, Cepeda C. 31.  et al. 2008. Full length human mutant Huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci. 28:6182–95 [Google Scholar]
  32. Gu X, Greiner ER, Mishra R. 32.  et al. 2009. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64:6828–40 [Google Scholar]
  33. Harper SQ, Staber PD, He X. 33.  et al. 2005. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA 102:165820–25 [Google Scholar]
  34. Pfister EL, Kennington L, Straubhaar J. 34.  et al. 2009. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol. 19:9774–78 [Google Scholar]
  35. Gu X, Li C, Wei W. 35.  et al. 2005. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron 46:3433–44 [Google Scholar]
  36. Gu X, André VM, Cepeda C. 36.  et al. 2007. Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2:8 [Google Scholar]
  37. Shoulson I, Odoroff C, Oakes D. 37.  et al. 1989. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease. Ann. Neurol. 25:3252–59 [Google Scholar]
  38. Peyser CE, Folstein M, Chase GA. 38.  et al. 1995. Trial of d-alpha-tocopherol in Huntington's disease. Am. J. Psychiatry 152:121771–75 [Google Scholar]
  39. Ranen NG, Peyser CE, Coyle JT. 39.  et al. 1996. A controlled trial of idebenone in Huntington's disease. Mov. Disord. 11:5549–54 [Google Scholar]
  40. Kremer B, Clark CM, Almqvist EW. 40.  et al. 1999. Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 53:51000–11 [Google Scholar]
  41. 41. Huntington Study Group 2001. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57:3397–404 [Google Scholar]
  42. Verbessem P, Lemiere J, Eijnde BO. 42.  et al. 2003. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61:7925–30 [Google Scholar]
  43. Puri BK, Leavitt BR, Hayden MR. 43.  et al. 2005. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65:2286–92 [Google Scholar]
  44. Landwehrmeyer GB, Dubois B, de Yébenes JG. 44.  et al. 2007. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann. Neurol. 62:3262–72 [Google Scholar]
  45. 45. Huntington Study Group DOMINO Investigators 2010. A futility study of minocycline in Huntington's disease. Mov. Disord. 25:132219–24 [Google Scholar]
  46. Hersch SM, Gevorkian S, Marder K. 46.  et al. 2006. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66:2250–52 [Google Scholar]
  47. 47. Huntington Study Group 2006. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66:3366–72 [Google Scholar]
  48. Mindham RH, Steele C, Folstein MF. 48.  et al. 1985. A comparison of the frequency of major affective disorder in Huntington's disease and Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 48:111172–74 [Google Scholar]
  49. Paulson JS, Hoth KF, Nehl C. 49.  et al. 2005. Critical periods of suicide risk in Huntington's disease. Am. J. Psychiatry 162(4):725–-31 [Google Scholar]
  50. Wexler A.50.  2008. The Woman Who Walked Into the Sea: Huntington's and the Making of a Genetic Disease126, 134, 160–61, 169 New Haven/London: Yale Univ. Press280
  51. Wexler AR.51.  2010. Stigma, history, and Huntington's disease. Lancet 376:973418–19 [Google Scholar]
  52. Kevles DJ.52.  1985. In the Name of Eugenics: Genetics and the Uses of Human Heredity New York: Alfred A. Knopf.426
  53. Davenport CB, Muncey EB. 53.  1916. Huntington's chorea in relation to heredity and eugenics. Am. J. Psychiatry 2:195 [Google Scholar]
  54. Critchley M.54.  1934. Huntington's chorea and East Anglia. J. State Med. 42:575–87 [Google Scholar]
/content/journals/10.1146/annurev-med-050710-134457
Loading
/content/journals/10.1146/annurev-med-050710-134457
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error